AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24268614
Drug: Cognitive Narrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Narrative Therapy (CNT) and Cognitive‐Behavioral Therapy (CBT)
Trial: 20421000
Drug: Completion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completion of combination therapy
Trial: 9671836
Drug: Oral electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral electronic thermometer
Trial: 7719091
Drug: Intraperitoneal perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal perfusion of compound injection of Salvia Miltiorrhiza before closing the abdominal cavity and Dachengqi decoction orally post-operatively
Trial: 7719091
Drug: Antibiotics intraperitoneally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics intraperitoneally before closing the abdominal cavity
Trial: 2680475
Drug: Five or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five or more cups of coffee daily for 4 weeks
Trial: 2680475
Drug: Five or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five or more cups of decaffeinated coffee daily for 4 weeks
Trial: 59627
Drug: 5-azacytidine (200-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-azacytidine (200-250 mg/m2/day X 5 i.v.)
Trial: 59627
Drug: guanazole (25-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guanazole (25-30 g/m2/day X 5 continuous i.v. infusion)
Trial: 31351345
Drug: Twice-weekly clinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly clinic visits
Trial: 31351345
Drug: Weekly clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly clinic visits
Trial: 19691545
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment group (waitlist control)
Trial: 23548422
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment of CHF
Trial: 21651760
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual without specific training (control condition)
Trial: 19349389
Drug: Talc slurry
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talc slurry (TS) administered through a chest tube
Trial: 16291715
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of escitalopram
Trial: 16291715
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of escitalopram (single or multiple doses)
Trial: 16291715
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of escitalopram
Trial: 16291715
Drug: Concurrent intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent intake of food with escitalopram
Trial: 10547226
Drug: CVT-1 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVT-1 at doses of 0, 300, 1500, and 3000 mg/day
Trial: 10547226
Drug: CVT-1 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVT-1 at 1000 mg three times daily for 2 weeks
Trial: 7799011
Drug: Eight-drugs-in-1-day chemotherapy
RxNorm normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight-drugs-in-1-day chemotherapy
Trial: 288486
Drug: Lithium carbonate,
RxNorm normalized name: Lithium Carbonate, 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium carbonate, 300 mg t.i.d.
Trial: 31585826
Drug: Cenegermin 20
RxNorm normalized name: CENEGERMIN 20 ug in 1 mL OPHTHALMIC SOLUTION/ DROPS [OXERVATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenegermin 20 μg/ml, 6 drops daily for 8 weeks
Trial: 31585826
Drug: Vehicle eye
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle eye drops, 6 drops daily for 8 weeks
Trial: 19268776
Drug: Low-dose doxycycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxycycline (50 mg/d)
Trial: 19268776
Drug: Medium-dose doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-dose doxycycline (100 mg/d)
Trial: 19268776
Drug: High-dose doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose doxycycline (300 mg/d)
Trial: 11535972
Drug: Sildenafil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil and L-Arginine
Trial: 9623550
Drug: Single-sample method
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-sample method for GFR >40 ml/min
Trial: 8146789
Drug: Intravascular laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular laser blood irradiation (ILBI) with helium-neon laser, daily procedures
Trial: 3292719
Drug: Vancomycin prophylaxis
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin prophylaxis (single prophylactic dose)
Trial: 3292719
Drug: No antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimicrobial agents (control group)
Trial: 30547766
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mirtazapine with SNRI or SSRI antidepressants
Trial: 30547766
Drug: SNRI or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNRI or SSRI therapy alone
Trial: 23973689
Drug: LDL-C levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C levels <70 mg/dl
Trial: 20234350
Drug: Celecoxib 16
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 16 mg/kg/day
Trial: 15705084
Drug: Darifenacin 7.5
RxNorm normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Darifenacin 7.5 mg
Trial: 16100298
Drug: Darifenacin 15
RxNorm normalized name: darifenacin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 15 mg
Trial: 15999217
Drug: Darifenacin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 30 mg
Trial: 7795833
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of weight loss and reduced sodium intake
Trial: 1781272
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for patients with increased basal and residual TR
Trial: 1781272
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for patients with increased basal TR but normal residual TR
Trial: 1781272
Drug: Aesthetic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aesthetic treatment for patients with normal total basal resistance
Trial: 25580924
Drug: Tetrabenazine (TBZ)
RxNorm normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (TBZ) 25-150 mg/d for 6 weeks
Trial: 23574533
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/day) plus nateglinide (PIO arm)
Trial: 23574533
Drug: Glimepiride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (2 mg/day) plus placebo (GLI arm)
Trial: 17338998
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose intravenously 200 mg once per week for 5 weeks
Trial: 17338998
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate 200 mg by mouth 3 times per day for 8 weeks
Trial: 15550791
Drug: Levosimendan low
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan low dose (12 microg/kg)
Trial: 15550791
Drug: Levosimendan high
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan high dose (24 microg/kg)
Trial: 11201872
Drug: Physical or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical or occupational therapy, reconstructive surgery, or temporary socioeconomic assistance
Trial: 11201872
Drug: Trials of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trials of alternative drugs or regimens for treating neuropathy
Trial: 1441872
Drug: 1% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% prilocaine (20 ml) for 3-in-1 block
Trial: 1441872
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml prilocaine for 3-in-1 block
Trial: 1441872
Drug: 35 ml
RxNorm normalized name: ethanol 0.35 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 ml prilocaine for 3-in-1 block
Trial: 3515918
Drug: Flurbiprofen, 100
RxNorm normalized name: Flurbiprofen, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen, 100 mg twice daily
Trial: 7932425
Drug: Naproxen, 250
RxNorm normalized name: Naproxen, 250 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen, 250 mg twice daily
Trial: 3515918
Drug: Flurbiprofen, 100
RxNorm normalized name: Flurbiprofen, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen, 100 mg twice daily (open-label phase)
Trial: 30745885
Drug: Exenatide 2
RxNorm normalized name: exenatide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg once-weekly (n = 23)
Trial: 22669847
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib with laser therapy
Trial: 27124881
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab monotherapy
Trial: 9713225
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy alone
Trial: 19728082
Drug: Fluvastatin high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin high dose (80 mg/day)
Trial: 19728082
Drug: Fluvastatin low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin low dose (20 mg/day)
Trial: 19728082
Drug: Fluvastatin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (both doses)
Trial: 10516867
Drug: Verapamil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (5 mg/hour intravenously for the first 24 hours, followed by 120 mg t.i.d. perorally for 6 months)
Trial: 7628095
Drug: Lecithin/sphingomyelin (L/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecithin/sphingomyelin (L/S) ratios
Trial: 2038732
Drug: Theophylline (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (twice a day)
Trial: 2038732
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (1 mg four times a day)
Trial: 27189615
Drug: Cryotherapy made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy made with chamomile infusion
Trial: 24666884
Drug: tolterodine/pilocarpine (2/9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine/pilocarpine (2/9 mg)
Trial: 24666884
Drug: tolterodine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine IR 2 mg
Trial: 24666884
Drug: tolterodine/pilocarpine (3/13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine/pilocarpine (3/13.5 mg)
Trial: 24666884
Drug: tolterodine extended-release
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine extended-release 4 mg
Trial: 21963581
Drug: Insulin multifaceted
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin multifaceted safety program
Trial: 18629370
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (an angiotensin II type 1 receptor blocker)
Trial: 18629370
Drug: Placebo (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (standard therapy)
Trial: 12900341
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE) 0.625 mg/d for 3 months
Trial: 12900341
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE) 0.3125 mg/d for 3 months
Trial: 1281259
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + porcine galanin (12.5 micrograms/min in 100 mL saline)
Trial: 1281259
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + saline (100 mL)
Trial: 1281259
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + galanin infusion
Trial: 6744948
Drug: Econazole nitrate
RxNorm normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Econazole nitrate 1.0 percent cream once a day
Trial: 31731677
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of health and environmental messages
Trial: 28826166
Drug: Myofascial trigger
RxNorm normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial trigger therapy (MT) combined with Cellconnect Impulse vibrotreatment
Trial: 28826166
Drug: Myofascial trigger
RxNorm normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial trigger therapy (MT)
Trial: 17106839
Drug: Acute psychiatric
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute psychiatric day-hospital treatment
Trial: 12214339
Drug: UDCA (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (15 mg/kg day)
Trial: 9790157
Drug: Citalopram (20+/−10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20+/−10 mg/day) during luteal phase only and placebo during follicular phase (intermittent treatment)
Trial: 9790157
Drug: Citalopram continuously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram continuously at a constant dosage (20+/−10 mg/day) throughout the menstrual cycle (continuous treatment)
Trial: 9790157
Drug: Citalopram continuously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram continuously throughout the cycle at a lower dosage in the follicular phases (5 mg/day) than in the luteal phases (20+/−10 mg/day) (semi-intermittent treatment)
Trial: 7615287
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy (n = 11)
Trial: 7615287
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (n = 10)
Trial: 7615287
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (n = 13)
Trial: 877819
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic povidone-iodine
Trial: 877819
Drug: Infusion site
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion site examination every eight hours
Trial: 877819
Drug: Infusion duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion duration
Trial: 23640589
Drug: 70 ml
RxNorm normalized name: ALCOHOL 70 mL TOPICAL SWAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 ml concentrated beetroot juice (BR)
Trial: 23640589
Drug: 140 ml
RxNorm normalized name: syringe, disposable, 140 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 140 ml concentrated beetroot juice (BR)
Trial: 23640589
Drug: 280 ml
RxNorm normalized name: ALCOHOL 280 mL in 400 mL TOPICAL GEL [Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 280 ml concentrated beetroot juice (BR)
Trial: 2704174
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d for 4 weeks
Trial: 9772612
Drug: Niaodujing (NDJ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaodujing (NDJ) treatment
Trial: 1656827
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (MACC: intravenous methotrexate, intravenous doxorubicin, intravenous cyclophosphamide, and oral lomustine) followed by thoracic radiotherapy
Trial: 1656827
Drug: Thoracic radiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic radiation therapy alone (5000 cGy in 5 weeks with a 1000 cGy boost)
Trial: 6408808
Drug: sulfinpyrazone (Anturan)
RxNorm normalized name: Sulfinpyrazone
DrugBank: Sulfinpyrazone (DB01138)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sulfinpyrazone (Anturan) 800 mg/die
Trial: 31381152
Drug: fosnetupitant 81
RxNorm normalized name: FOSNETUPITANT
DrugBank: Fosnetupitant (DB14019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fosnetupitant 81 mg
Trial: 28776431
Drug: Internet-based cognitive-behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavior therapy with therapist support (n=20)
Trial: 28776431
Drug: Internet-based cognitive-behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavior therapy without therapist support (n=22)
Trial: 27838685
Drug: Personalized, spectrally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized, spectrally altered classical music therapy
Trial: 24390009
Drug: Low-intensity pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pulsed ultrasound (LIPUS) for 20 minutes daily during treatment
Trial: 24390009
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without LIPUS treatment
Trial: 22646847
Drug: Olanzapine long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine long-acting injection (405 mg/4 weeks, 210 or 300 mg/2 weeks)
Trial: 22646847
Drug: Oral olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine (10 ± 2.5 or 15 ± 2.5 mg/day)
Trial: 22646847
Drug: Haloperidol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (15 ± 5 mg/day)
Trial: 22339430
Drug: Oral olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine
Trial: 19387396
Drug: HMB supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB supplementation (3 g/d)
Trial: 18088023
Drug: Active sublingual
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active sublingual immunotherapy with SLITone grass mix plus olive pollen extract for 6 months
Trial: 31324206
Drug: Penile topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penile topical metronidazole
Trial: 19909586
Drug: Single-dose GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose GnRH agonist (0.5 mg leuprolide acetate) administered subcutaneously on day 6 after ICSI
Trial: 19909586
Drug: Standard luteal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard luteal support (intravaginal 600 mg micronized progesterone) without GnRH agonist
Trial: 19909586
Drug: Single-dose GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose GnRH agonist
Trial: 16736388
Drug: Conventional antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antidepressants (CA, mainly SSRIs)
Trial: 16094658
Drug: Conventional antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antidepressants (CA)
Trial: 16035398
Drug: Nimesulide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide and Ibuprofen (both)